Pharmacists may earn 1.50 CPE Credit (0.15 CEU) by completing this course on the American Society of Health-System Pharmacists (ASHP) website. Please click here to go to the course (you will leave the myCME website, and free registration on the ASHP website is required). Your certificate will save on ASHP.org and will not be included in your myCME CME History.
This continuing medical education activity is provided by the American Society of Health-System Pharmacists (ASHP).
Supported by an educational grant from Merck.
Clostridium difficile infection (CDI) is the most common healthcare associated infection the United States and the most common cause of mortality in patients with gastroenteritis. Treatment of CDI is evolving with a greater emphasis on prevention of recurrence also known as sustained clinical response. These changes will require education to clinicians on these major changes.
In this educational activity, expert faculty navigate challenges of managing patients with CDI using patient cases to illustrate the correlation of CDI and overuse of antibiotics, discusses the application of new treatment guidelines, and reviews the role of newer therapies in CDI treatment.
This activity was planned to meet the educational needs of physicians, pharmacists, physician assistants, and nurse practitioners involved in the treatment of patients with Clostridium difficile infection.
At the conclusion of this application-based educational activity, participants should be able to:
Describe the correlation of Clostridium difficile Infection (CDI) and overuse of antibiotics.
Apply new treatment guidelines to treat patients with CDI.
Evaluate the use of vancomycin and fidaxomicin for the primary treatment of CDI.
Discuss the role of newer therapies in the treatment of CDI.
Conflict Of Interest Disclosure Policy
In accordance with ACCME and ACPE Standards for Commercial Support, ASHP policy requires that all faculty, planners, reviewers, staff, and others in a position to control the content of this presentation disclose their financial relationships.
Dr. Rao discloses the following: Research support (Co-investigator): Merck, Inc. Advisor Board Member: Merck, Inc. Research funding received: Merck, Inc.
Accredited Provider Disclosure
The planners and managers reported no financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity.
AMA PRA Category 1 Credit(s)TM
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American Society of Health-System Pharmacists designates this enduring material for a maximum of 1.50 AMA PRA Category 1 CreditsTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
In order to receive credit, participants must complete the pre-assessment questions, post-assessment questions, and program evaluation. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.
For information about the accreditation of this program, please contact email@example.com.